CliffBio
small molecule

VIBATIV

TELAVANCIN HYDROCHLORIDE

Loss of exclusivityJanuary 2027latest FDA-listed patent expiry
CompanyCumberland →View the full company profile on CliffBio

Drug detail

Brand nameVIBATIV
Active ingredientTELAVANCIN HYDROCHLORIDE
StrengthEQ 250MG BASE/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalSeptember 2009
Marketing statusDISCN

Listed patents

PatentExpiresType
7531623January 2027substance

More from Cumberland

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VIBATIV patent cliff — loss of exclusivity January 2027 | CliffBio